These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35215442)

  • 1. Understanding Neurodegeneration from a Clinical and Therapeutic Perspective in Early Diabetic Retinopathy.
    Fragiotta S; Pinazo-Durán MD; Scuderi G
    Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurodegeneration in diabetic retinopathy: does it really matter?
    Simó R; Stitt AW; Gardner TW
    Diabetologia; 2018 Sep; 61(9):1902-1912. PubMed ID: 30030554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms Mediating Diabetic Retinal Neurodegeneration: Potential Research Avenues and Therapeutic Targets.
    Chakravarthy H; Devanathan V
    J Mol Neurosci; 2018 Nov; 66(3):445-461. PubMed ID: 30293228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin replacement: a new strategy for treating diabetic retinopathy.
    Hernández C; Simó R;
    Curr Med Chem; 2013; 20(26):3251-7. PubMed ID: 23745546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR.
    Grauslund J; Frydkjaer-Olsen U; Peto T; Fernández-Carneado J; Ponsati B; Hernández C; Cunha-Vaz J; Simó R;
    Invest Ophthalmol Vis Sci; 2019 May; 60(6):2257-2262. PubMed ID: 31112610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy.
    Beltramo E; Lopatina T; Mazzeo A; Arroba AI; Valverde AM; Hernández C; Simó R; Porta M
    Acta Diabetol; 2016 Dec; 53(6):957-964. PubMed ID: 27552833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal Neurodegeneration as an Early Manifestation of Diabetic Eye Disease and Potential Neuroprotective Therapies.
    Zafar S; Sachdeva M; Frankfort BJ; Channa R
    Curr Diab Rep; 2019 Feb; 19(4):17. PubMed ID: 30806815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic retinopathy: neuron protection as a therapeutic target.
    Zhang X; Wang N; Barile GR; Bao S; Gillies M
    Int J Biochem Cell Biol; 2013 Jul; 45(7):1525-9. PubMed ID: 23506699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives.
    Simó R; Hernández C;
    Trends Endocrinol Metab; 2014 Jan; 25(1):23-33. PubMed ID: 24183659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Liposomal Formulation of Citicoline in Experimental Diabetes-Induced Retinal Neurodegeneration.
    Bogdanov P; Sampedro J; Solà-Adell C; Simó-Servat O; Russo C; Varela-Sende L; Simó R; Hernández C
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30127248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications.
    Simó R; Hernández C;
    Br J Ophthalmol; 2012 Oct; 96(10):1285-90. PubMed ID: 22887976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurodegeneration as a primary change and role of neuroprotection in diabetic retinopathy.
    Jindal V
    Mol Neurobiol; 2015; 51(3):878-84. PubMed ID: 24826918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection for diabetic retinopathy.
    Imai H; Singh RSJ; Fort PE; Gardner TW
    Dev Ophthalmol; 2009; 44():56-68. PubMed ID: 19494653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection as a Therapeutic Target for Diabetic Retinopathy.
    Hernández C; Dal Monte M; Simó R; Casini G
    J Diabetes Res; 2016; 2016():9508541. PubMed ID: 27123463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy.
    Rolev KD; Shu XS; Ying Y
    Neuropharmacology; 2021 Apr; 187():108498. PubMed ID: 33582150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial.
    Simó R; Hernández C; Porta M; Bandello F; Grauslund J; Harding SP; Aldington SJ; Egan C; Frydkjaer-Olsen U; García-Arumí J; Gibson J; Lang GE; Lattanzio R; Massin P; Midena E; Ponsati B; Ribeiro L; Scanlon P; Lobo C; Costa MÂ; Cunha-Vaz J;
    Diabetes; 2019 Feb; 68(2):457-463. PubMed ID: 30389750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The state of ocular neurosensory apparatus in diabetes mellitus].
    Sdobnikova SV; Kulybysheva VS; Sidamonidze AL
    Vestn Oftalmol; 2018; 134(5. Vyp. 2):263-269. PubMed ID: 30499527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal Neurodegeneration in Diabetes: an Emerging Concept in Diabetic Retinopathy.
    Sachdeva MM
    Curr Diab Rep; 2021 Dec; 21(12):65. PubMed ID: 34902066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence.
    Simó R; Hernández C
    Prog Retin Eye Res; 2015 Sep; 48():160-80. PubMed ID: 25936649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegeneration and Neuroinflammation in Diabetic Retinopathy: Potential Approaches to Delay Neuronal Loss.
    Kadłubowska J; Malaguarnera L; Wąż P; Zorena K
    Curr Neuropharmacol; 2016; 14(8):831-839. PubMed ID: 27306035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.